ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...
Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024). LITESPARK-005, KEYNOTE-564, TIVO-3, CLEAR, CHECKMATE-9ER, ...
Quality of Life in Head and Neck Cancer Patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35 PURPOSE: To prospectively evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results